SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Aquilo Capital Management, LLC

CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140

Reported Value
$551M
Q3 2021
Positions
14
Filings on Record
27
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Aquilo Capital Management, LLC reported $551M in U.S.-listed holdings across 14 positions for Q3 2021.

Its largest position, SPRO, represents 15.3% of the portfolio.

Compared with Q2 2021, the fund opened 2 new positions and exited 3.

Portfolio Metrics

Turnover
+14.5%
vs prior filed quarter
Top-10 Concentration
+71.9%
share of reported value
Largest Position
+15.3%
Spero Therapeutics
New / Exited
2 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $226MQ1 ’19Q2 ’19: $288MQ3 ’19: $142MQ4 ’19: $266MQ1 ’20: $257MQ1 ’20Q2 ’20: $496MQ3 ’20: $945MQ4 ’20: $481MQ1 ’21: $553MQ1 ’21Q2 ’21: $385MQ3 ’21: $551MQ4 ’21: $882MQ1 ’22: $680MQ1 ’22Q2 ’22: $293MQ3 ’22: $277MQ4 ’22: $266MQ1 ’23: $241MQ1 ’23Q2 ’23: $180MQ3 ’23: $110MQ4 ’23: $160MQ1 ’24: $133MQ1 ’24Q2 ’24: $104MQ3 ’24: $132MQ4 ’24: $66MQ1 ’25: $56MQ1 ’25Q2 ’25: $0Q3 ’25: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.7%ETP: 22.8%Other: 7.2%ADR: 2.2%
  • Common Stock · 67.7% · $373M
  • ETP · 22.8% · $126M
  • Other · 7.2% · $40M
  • ADR · 2.2% · $12M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
XBISPDR S&P BIOTECH ETF TRNEW+1.00M1.00M+$126M$126M
ARVNARVINAS INCNEW+354.7K354.7K+$29M$29M
NGM BIOPHARMACEUTICALS INCSOLD OUT−1.19M0−$24M$0
HARPOON THERAPEUTICS INCSOLD OUT−712.7K0−$10M$0
GALAPAGOS NVSOLD OUT−142.3K0−$10M$0
RGNXREGENXBIO INCADDED+243.7K839.1K+$12M$35M
DICERNA PHARMACEUTICALS INCADDED+643.2K2.46M−$18M$50M
ARWRARROWHEAD PHARMACEUTICALS INCADDED+95.0K527.9K−$3M$33M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPROSPERO THERAPEUTICS INChistory →COM15.26%$84M4.56M
2BLUEPRINT MEDICINES CORPCOM9.74%$54M521.7K
3DICERNA PHARMACEUTICALS INCCOM8.99%$50M2.46M
4QUREUNIQURE NVhistory →SHS7.67%$42M1.32M
5RGNXREGENXBIO INChistory →COM6.39%$35M839.1K
6ARWRARROWHEAD PHARMACEUTICALS INChistory →COM5.99%$33M527.9K
7FDMT4D MOLECULAR THERAPEUTICS INChistory →COM5.39%$30M1.10M
8ARVNARVINAS INChistory →COM5.29%$29M354.7K
9MAGENTA THERAPEUTICS INCCOM4.17%$23M3.16M
10AMRYT PHARMA PLCSPONSORED ADS3.04%$17M1.39M
11PIERIS PHARMACEUTICALS INCCOM3.00%$17M3.20M
12ARGXARGENX SEhistory →SPONSORED ADR1.22%$7M22.2K
13GMABGENMAB A/Shistory →SPONSORED ADS1.01%$6M127.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$01Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 6, 202513F-HRchanges · EDGAR ↗
Q1 2025$56M13May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$66M15Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$132M14Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$104M13Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$133M10May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$160M10Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$110M12Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$180M13Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$241M12May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$266M13Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$277M15Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$293M13Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$680M14May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$882M14Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$551M14Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$385M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$553M17May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$481M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$945M17Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$496M14Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$257M14May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$266M12Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M11Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$288M13Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$226M14May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.